ADvantage Therapeutics Inc.
Tuesday, June 04, 2024
CNS/Neurological
Company Presentation Theater 1
ADvantage Therapeutics (ADTx) is developing therapies to treat neurodegenerative conditions with a central focus on Alzheimer’s Disease (AD).
The Company’s lead compound AD04™ is a subcutaneous injectable therapy that has entered confirmatory Phase 2b clinical trials in Europe, to evaluate its safety and efficacy in early AD patients. The Company believes that AD04™ may function as an immunomodulator, stimulating and regulating the immune system to reduce AD pathology, indirectly triggering the elimination of misfolded proteins, beta amyloid and tau.
Based in Miami with a research subsidiary in Vienna, the Company conducts early research and drug development to explore additional approaches to mitigating neurodegenerative disease, among them increasing the levels of Klotho, a life and health extending protein with an overall impact on longevity.
Company Website:
http://www.advantagetherapeutics.com
Lead Product in Development:
AD04. A small molecule in phase EU (UK with ILAP fast track designation) for mild Alzheimer's Disease.
Klotho mRNA, to generate endogenous Klotho, the "anti-aging hormone", involved in a variety of organ regeneration mechanisms: kidneys, brain, etc.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
AD04. A small molecule in phase EU (UK with ILAP fast track designation) for mild Alzheimer's Disease.
Klotho mRNA, to generate endogenous Klotho, the "anti-aging hormone", involved in a variety of organ regeneration mechanisms: kidneys, brain, etc.
Company HQ City
Miami
Company HQ State
Florida
Company HQ Country
United States
CEO/Top Company Official
Jeffrey B. Madden
Development Phase of Primary Product
Phase II
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())